 | • レポートコード：MRC2301F0078 • 出版社/出版日：Transparency Market Research / 2022年10月11日 • レポート形態：英文、PDF、243ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トランスペアレンシー・マーケット・リサーチ社の当調査資料では、世界の眼科用医薬品市場について総合的に調査・分析を行い、序論、仮定・調査手法、市場概要、主要インサイト、疾患別（ドライアイ、緑内障、感染症＆炎症、網膜疾患、その他）分析、治療区分別（抗炎症剤、抗感染症薬、緑内障治療薬、抗アレルギー剤、その他）分析、商品タイプ別（医療用医薬品、OTC医薬品）分析、流通チャネル別（病院薬局、オンライン薬局、独立系薬局＆ドラッグストア）分析、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東/アフリカ）分析、競争状況、企業情報などの項目を掲載しています。なお、当市場の主要企業には、Aerie Pharmaceuticals, Inc.、Allergan plc、Valeant Pharmaceuticals International, Inc.、Bayer AG、Genentech, Inc. (F. Hoffmann-La Roche Ltd.)、Novartis AG、Pfizer Inc.、Regeneron Pharmaceuticals, Inc.、Santen Pharmaceutical Co., Ltd.などが含まれています。 ・序論 ・仮定・調査手法 ・市場概要 ・主要インサイト ・世界の眼科用医薬品市場規模：疾患別 - ドライアイにおける市場規模 - 緑内障における市場規模 - 感染症＆炎症における市場規模 - 網膜疾患における市場規模 - その他疾患における市場規模 ・世界の眼科用医薬品市場規模：治療区分別 - 抗炎症剤治療の市場規模 - 抗感染症薬治療の市場規模 - 緑内障治療薬治療の市場規模 - 抗アレルギー剤治療の市場規模 - その他治療区分の市場規模 ・世界の眼科用医薬品市場規模：商品タイプ別 - 医療用医薬品の市場規模 - OTC医薬品の市場規模 ・世界の眼科用医薬品市場規模：流通チャネル別 - 病院薬局の市場規模 - オンライン薬局の市場規模 - 独立系薬局＆ドラッグストアの市場規模 ・世界の眼科用医薬品市場規模：地域別 - 北米の眼科用医薬品市場規模 - 中南米の眼科用医薬品市場規模 - ヨーロッパの眼科用医薬品市場規模 - アジア太平洋の眼科用医薬品市場規模 - 中東/アフリカの眼科用医薬品市場規模 ・競争状況 ・企業情報 |
Ophthalmic Drugs Market – Scope of Report
TMR’s report on the global ophthalmic drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global ophthalmic drugs market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ophthalmic drugs market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the ophthalmic drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ophthalmic drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global ophthalmic drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ophthalmic drugs market.
The report delves into the competitive landscape of the global ophthalmic drugs market. Key players operating in the global ophthalmic drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ophthalmic drugs market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market ophthalmic drugs.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ophthalmic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Indication Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ophthalmic Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. Key Mergers & Acquisitions
5.5. COVID-19 Impact
6. Global Ophthalmic Drugs Market Analysis and Forecast, By Disease Indication
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast By Disease Indication, 2017–2031
6.3.1. Dry Eye
6.3.2. Glaucoma
6.3.3. Infection/Inflammation
6.3.4. Retinal Disorders
6.3.4.1. Wet AMD
6.3.4.2. Dry AMD
6.3.4.3. Diabetic Retinopathy
6.3.4.4. Others
6.3.5. Allergy
6.3.6. Uveitis
6.3.7. Others
6.4. Market Attractiveness By Disease Indication
7. Global Ophthalmic Drugs Market Analysis and Forecast, By Therapeutic Class
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast By Therapeutic Class, 2017–2031
7.3.1. Anti-inflammatory Drugs
7.3.1.1. NSAIDs
7.3.1.2. Steroids
7.3.2. Anti-infective Drugs
7.3.2.1. Anti-fungal Drugs
7.3.2.2. Anti-bacterial Drugs
7.3.2.3. Others
7.3.3. Anti-glaucoma Drugs
7.3.3.1. Alpha Agonist
7.3.3.2. Beta Blockers
7.3.3.3. Prostaglandin Analogs
7.3.3.4. Combined Medication
7.3.3.5. Others
7.3.4. Anti-allergy Drugs
7.3.5. Anti-VEGF Agents
7.3.6. Others
7.4. Market Attractiveness By Therapeutic Class
8. Global Ophthalmic Drugs Market Analysis and Forecast, By Product Type
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast By Product Type, 2017–2031
8.3.1. Prescription Drugs
8.3.2. OTC Drugs
8.4. Market Attractiveness By Product Type
9. Global Ophthalmic Drugs Market Analysis and Forecast, By Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast By Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Online Pharmacies
9.3.3. Independent Pharmacies & Drug Stores
9.4. Market Attractiveness By Distribution Channel
10. Global Ophthalmic Drugs Market Analysis and Forecast, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Ophthalmic Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Disease Indication, 2017–2031
11.2.1. Dry Eye
11.2.2. Glaucoma
11.2.3. Infection/Inflammation
11.2.4. Retinal Disorders
11.2.4.1. Wet AMD
11.2.4.2. Dry AMD
11.2.4.3. Diabetic Retinopathy
11.2.4.4. Others
11.2.5. Allergy
11.2.6. Uveitis
11.2.7. Others
11.3. Market Value Forecast By Therapeutic Class, 2017–2031
11.3.1. Anti-inflammatory Drugs
11.3.1.1. NSAIDs
11.3.1.2. Steroids
11.3.2. Anti-infective Drugs
11.3.2.1. Anti-fungal Drugs
11.3.2.2. Anti-bacterial Drugs
11.3.2.3. Others
11.3.3. Anti-glaucoma Drugs
11.3.3.1. Alpha Agonist
11.3.3.2. Beta Blockers
11.3.3.3. Prostaglandin Analogs
11.3.3.4. Combined Medication
11.3.3.5. Others
11.3.4. Anti-allergy Drugs
11.3.5. Anti-VEGF Agents
11.3.6. Others
11.4. Market Value Forecast By Product Type, 2017–2031
11.4.1. Prescription Drugs
11.4.2. OTC Drugs
11.5. Market Value Forecast By Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Online Pharmacies
11.5.3. Independent Pharmacies & Drug Stores
11.6. Market Value Forecast By Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Disease Indication
11.7.2. By Therapeutic Class
11.7.3. By Product Type
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Ophthalmic Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Disease Indication, 2017–2031
12.2.1. Dry Eye
12.2.2. Glaucoma
12.2.3. Infection/Inflammation
12.2.4. Retinal Disorders
12.2.4.1. Wet AMD
12.2.4.2. Dry AMD
12.2.4.3. Diabetic Retinopathy
12.2.4.4. Others
12.2.5. Allergy
12.2.6. Uveitis
12.2.7. Others
12.3. Market Value Forecast By Therapeutic Class, 2017–2031
12.3.1. Anti-inflammatory Drugs
12.3.1.1. NSAIDs
12.3.1.2. Steroids
12.3.2. Anti-infective Drugs
12.3.2.1. Anti-fungal Drugs
12.3.2.2. Anti-bacterial Drugs
12.3.2.3. Others
12.3.3. Anti-glaucoma Drugs
12.3.3.1. Alpha Agonist
12.3.3.2. Beta Blockers
12.3.3.3. Prostaglandin Analogs
12.3.3.4. Combined Medication
12.3.3.5. Others
12.3.4. Anti-allergy Drugs
12.3.5. Anti-VEGF Agents
12.3.6. Others
12.4. Market Value Forecast By Product Type, 2017–2031
12.4.1. Prescription Drugs
12.4.2. OTC Drugs
12.5. Market Value Forecast By Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Online Pharmacies
12.5.3. Independent Pharmacies & Drug Stores
12.6. Market Value Forecast By Country, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Disease Indication
12.7.2. By Therapeutic Class
12.7.3. By Product Type
12.7.4. By Distribution Channel
12.7.5. By Country
13. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Disease Indication, 2017–2031
13.2.1. Dry Eye
13.2.2. Glaucoma
13.2.3. Infection/Inflammation
13.2.4. Retinal Disorders
13.2.4.1. Wet AMD
13.2.4.2. Dry AMD
13.2.4.3. Diabetic Retinopathy
13.2.4.4. Others
13.2.5. Allergy
13.2.6. Uveitis
13.2.7. Others
13.3. Market Value Forecast By Therapeutic Class, 2017–2031
13.3.1. Anti-inflammatory Drugs
13.3.1.1. NSAIDs
13.3.1.2. Steroids
13.3.2. Anti-infective Drugs
13.3.2.1. Anti-fungal Drugs
13.3.2.2. Anti-bacterial Drugs
13.3.2.3. Others
13.3.3. Anti-glaucoma Drugs
13.3.3.1. Alpha Agonist
13.3.3.2. Beta Blockers
13.3.3.3. Prostaglandin Analogs
13.3.3.4. Combined Medication
13.3.3.5. Others
13.3.4. Anti-allergy Drugs
13.3.5. Anti-VEGF Agents
13.3.6. Others
13.4. Market Value Forecast By Product Type, 2017–2031
13.4.1. Prescription Drugs
13.4.2. OTC Drugs
13.5. Market Value Forecast By Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Online Pharmacies
13.5.3. Independent Pharmacies & Drug Stores
13.6. Market Value Forecast By Country, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Disease Indication
13.7.2. By Therapeutic Class
13.7.3. By Product Type
13.7.4. By Distribution Channel
13.7.5. By Country
14. Latin America Ophthalmic Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Disease Indication, 2017–2031
14.2.1. Dry Eye
14.2.2. Glaucoma
14.2.3. Infection/Inflammation
14.2.4. Retinal Disorders
14.2.4.1. Wet AMD
14.2.4.2. Dry AMD
14.2.4.3. Diabetic Retinopathy
14.2.4.4. Others
14.2.5. Allergy
14.2.6. Uveitis
14.2.7. Others
14.3. Market Value Forecast By Therapeutic Class, 2017–2031
14.3.1. Anti-inflammatory Drugs
14.3.1.1. NSAIDs
14.3.1.2. Steroids
14.3.2. Anti-infective Drugs
14.3.2.1. Anti-fungal Drugs
14.3.2.2. Anti-bacterial Drugs
14.3.2.3. Others
14.3.3. Anti-glaucoma Drugs
14.3.3.1. Alpha Agonist
14.3.3.2. Beta Blockers
14.3.3.3. Prostaglandin Analogs
14.3.3.4. Combined Medication
14.3.3.5. Others
14.3.4. Anti-allergy Drugs
14.3.5. Anti-VEGF Agents
14.3.6. Others
14.4. Market Value Forecast By Product Type, 2017–2031
14.4.1. Prescription Drugs
14.4.2. OTC Drugs
14.5. Market Value Forecast By Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Online Pharmacies
14.5.3. Independent Pharmacies & Drug Stores
14.6. Market Value Forecast By Country, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Disease Indication
14.7.2. By Therapeutic Class
14.7.3. By Product Type
14.7.4. By Distribution Channel
14.7.5. By Country
15. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Disease Indication, 2017–2031
15.2.1. Dry Eye
15.2.2. Glaucoma
15.2.3. Infection/Inflammation
15.2.4. Retinal Disorders
15.2.4.1. Wet AMD
15.2.4.2. Dry AMD
15.2.4.3. Diabetic Retinopathy
15.2.4.4. Others
15.2.5. Allergy
15.2.6. Uveitis
15.2.7. Others
15.3. Market Value Forecast By Therapeutic Class, 2017–2031
15.3.1. Anti-inflammatory Drugs
15.3.1.1. NSAIDs
15.3.1.2. Steroids
15.3.2. Anti-infective Drugs
15.3.2.1. Anti-fungal Drugs
15.3.2.2. Anti-bacterial Drugs
15.3.2.3. Others
15.3.3. Anti-glaucoma Drugs
15.3.3.1. Alpha Agonist
15.3.3.2. Beta Blockers
15.3.3.3. Prostaglandin Analogs
15.3.3.4. Combined Medication
15.3.3.5. Others
15.3.4. Anti-allergy Drugs
15.3.5. Anti-VEGF Agents
15.3.6. Others
15.4. Market Value Forecast By Product Type, 2017–2031
15.4.1. Prescription Drugs
15.4.2. OTC Drugs
15.5. Market Value Forecast By Distribution Channel, 2017–2031
15.5.1. Hospital Pharmacies
15.5.2. Online Pharmacies
15.5.3. Independent Pharmacies & Drug Stores
15.6. Market Value Forecast By Country, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Disease Indication
15.7.2. By Therapeutic Class
15.7.3. By Product Type
15.7.4. By Distribution Channel
15.7.5. By Country
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Aerie Pharmaceuticals, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Allergan plc
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Valeant Pharmaceuticals International, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. Bayer AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. Novartis AG.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. Pfizer Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Regeneron Pharmaceuticals, Inc
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
16.3.9. Santen Pharmaceutical Co., Ltd
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Strategic Overview